Professor Joy Ho

Clinical Professor
Medicine, Central Clinical School

Telephone +61 2 9515 8031
Fax +61 2 9515 8474

Map

Selected grants

2014

  • CLARIOstar Multifunctional Microplate Reader for Shared Used at the Open Access, Multi-User Molecular Biology Core Facility; Huang M, Scolyer R, Fraser S, Sahni S, Speranza T, Owens T, Barrs V, Ju Y, Kovacevic Z, Lu Z, Camp A, Slobedman B, Morris B, Oliver B, Dos Remedios C, Kalinowski D, Fu D, Lai D, Lovicu F, Allbutt H, Triccas J, Burgess J, Kril J, Dixon K, Rendina L, Byrne M, King N, Groundwater P, Williamson P, Ho J, Dong Q, Bao B, Assinder S, McLennan S, Richardson D, Ammit A, Sharland A, Hardikar A, Hong A, Hambly B, Lee C, Murphy C, Goldsbury C, Johnstone D, Lane D, Hibbs D, Joshua D, Huq F, Halliday G, Sutherland G, Zreiqat H, Lok H, Lyons G, Jansson P, Black J, Zhu L, Sunde M, Day M, Naylor M, Buckland M, Murray M, Shafie N, Lay P, Poronnik P, Codd R, Mason R, Ryan R, Christopherson R, de Graaf S; National Health and Medical Research Council (NHMRC)/Equipment Grants.

2013

  • Robotic High Throughput Western Analysis for the Open Access, Multi-User Sydney Cancer Research Core Facility; Richardson D, Scolyer R, Boyer M, Halliday G, Damian D, Christopherson R, Joshua D, Kench J, Hong A, Murray M, Lee C, Kalinowski D, Naylor M, Lay P, Lyons G, Kovacevic Z, Mason R, Dixon K, Chan-Ling T, Hawkins C, Sunde M, Lovejoy D, Owens T, Rendina L, Jansson P, Dos Remedios C, Charles (nee Slaviero) K, Lane D, Witting P, Dong Q, Ammit A, Groundwater P, Assinder S, Bao B, Byrne S, Zhou F, Buckland M, Grewal T, Huq F, Lai D, Codd R, Zhang D, Fu D, de Graaf S, Huang M, Payne R, Slobedman B, Barrs V, Ho J, Williamson P, Murphy C; DVC Research/Equipment Grant.

2007

  • Rotor-Gene 6000, 5-Plex HRM with desktop computer & Gene-Disc 100 Stater Kit; Halliday G, Yue D, Sharland A, Bishop A, Stocker R, Bao B, McLennan S, Matsumoto I, Hambly B, Rose B, Harbour C, Ho J, Lee C, Twigg S, Soon L, Richardson D, King N, Zreiqat H; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • PHERAstar and POLARstar Optima multi-functional plate readers with robotic high throughput screening system for multi-disciplinary cancer research; Halliday G, Ho J, Conigrave A, Iland H, Lee C, Joshua D, Cook D, Richardson D, Reichardt J, Grau G, Lovejoy D, Hunt N, King N, Mason R, Murphy C, Sharland A, Assinder S, Dong Q, Bishop A; Cancer Institute New South Wales/Infrastructure Grant.

2002

  • Switch translocations in myeloma; Ho J; University of Sydney/Cancer Research Fund.

Selected publications

Download citations: PDF RTF Endnote

Books

  • Ho, J. (2005). Multiple Myeloma: Methods and Protocols. Totowa, NJ, USA: Humana Press.

Book Chapters

  • Ling, S., Campbell, L., Ho, J., Gibson, J., Joshua, D. (2007). Molecular Biology, Pathology, and Cytogenetics. In Mikkael A. Sekeres, Matt E. Kalaycio, Brian J. Bolwell (Eds.), Clinical Malignant Haematology, (pp. 847-857). United States: McGraw Hill.
  • Gibson, J., Joshua, D., Ho, J., Campbell, L., Ling, S. (2005). Multiple Myeloma: molecular biology, Pathology and Cytogenics. In Susan Hallam, Ian Cross, Michael Thaut (Eds.), Oxford Handbook of Music Psychology. Oxford, UK: Oxford University Press.
  • Joshua, D., Gibson, J., Brown, R., Ho, J. (2004). The Immune System In Myeloma. In Gosta Garton, Brian Durie, Diana Samson (Eds.), Multiple myeloma and related disorders, (pp. 29-46). UK: Hodder Arnold.

Journals

  • Favaloro, J., Brown, R., Aklilu, E., Yang, S., Suen, H., Hart, D., Fromm, P., Gibson, J., Khoo, L., Ho, J., Joshua, D. (2014). Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive state. Leukemia and Lymphoma, 55(5), 1090-1098. [More Information]
  • Bryant, C., Suen, H., Brown, R., Yang, S., Favaloro, J., Aklilu, E., Gibson, J., Ho, J., Iland, H., Fromm, P., Hart, D., Joshua, D., et al (2013). Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance. Blood Cancer Journal, 3, 1-7. [More Information]
  • Ling, S., Lau, K., Al-Shabeeb, A., Nikolic, A., Catalano, A., Iland, H., Horvath, N., Ho, J., Harrison, S., Fleming, S., Joshua, D., Allen, J. (2012). Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1. Haematologica: the hematology journal, 97(1), 64-72. [More Information]
  • Ho, J., Brown, R., Spencer, A., Jeffels, M., Daniher, D., Gibson, J., Joshua, D. (2012). Thalidomide consolidation improves progression-free survival in myeloma with normal but not up-regulated expression of fibroblast growth factor receptor 3: analysis from the Australasian Leukaemia and Lymphoma Group MM6 clinical trial. Leukemia and Lymphoma, 53(9), 1728-1734. [More Information]
  • Ho, J., Tay, L., Lindeman, R., Catley, L., Bowden, D. (2011). Australian guidelines for the assessment of iron overload and iron chelation in transfusion-dependent thalassaemia major, sickle cell disease and other congenital anaemias. Internal Medicine Journal, 41(7), 516-524. [More Information]
  • Viprakasit, V., Ibrahim, H., Ha, S., Ho, J., Li, C., Chan, L., Chiu, C., Sutcharitchan, P., Habr, D., Domokos, G., et al (2011). Clinical efficacy and safety evaluation of tailoring iron chelation practice in thalassaemia patients from Asia-Pacific: a subanalysis of the EPIC study of deferasirox. International Journal of Hematology (online), 93(3), 319-328. [More Information]
  • Loh, Y., Mo, S., Brown, R., Yamagishi, T., Yang, S., Joshua, D., Ho, P., Gibson, J., Roufogalis, B., Sze, D. (2007). Characteristics of 'side population' as the putative cancer stem cells in myeloma: Cell growth and differentiation capability. Molecular Cancer Therapeutics, 6(12), 3365s-3366s.
  • Sanders, J., Crawford, B., Gibson, J., Ho, J., Iland, H., Joshua, D. (2007). Is there a case for the early use of bisphosphonates in smouldering myeloma and MGUS? (Bisphosphonates in SMM & MGUS). International Journal of Laboratory Hematology, 29(5), 395-397. [More Information]
  • Osborn, R., de Abreu Lourenço, R., Dalton, A., Houltram, J., Dowton, D., Joshua, D., Lindeman, R., Ho, J. (2007). Quality of life related to oral versus subcutaneous iron chelation: a time trade-off study. Value in Health, 10(6), 451-456. [More Information]
  • Trent, R., Webster, B., Bowden, D., Gilbert, A., Ho, J., Lindeman, R., Lammi, A., Rowell, J., Hinchcliffe, M., Colley, A., et al (2006). Complex phenotypes in the haemoglobinopathies: recommendations on screening and DNA testing. Pathology, 38(6), 507-519.
  • Sze, D., Brown, R., Yang, S., Ho, J., Gibson, J., Joshua, D. (2006). The use of thalidomide in myeloma therapy as an effective anticancer drug. Current Cancer Drug Targets, 6(4), 325-331. [More Information]
  • Ling, S., Joshua, D., Gibson, J., Young, G., Iland, H., Watson, G., Ho, J. (2006). Transformation and Progression of Waldenström's Macroglobulinemia Following Cladribine Therapy in Two Cases: Natural Evolution or Iatrogenic Causation? American Journal Of Hematology, 81(2), 110-114. [More Information]
  • Brown, R., Ho, J. (2005). Identification of Malignant Plasma Cells by mRNA In Situ Hybridization. Methods in molecular medicine, 113, 175-181.
  • Joshua, D., Brown, R., Ho, J. (2005). Multiple myeloma: challenges and opportunities. Methods in molecular medicine, 113(Multiple Myeloma: Methods and Protocols), 1-4.
  • Brown, R., Murray, A., Pope, B., Sze, D., Gibson, J., Ho, J., Joshua, D. (2004). B7+ T Cells In Myeloma: An Acquired Marker Of Prior Chronic Antigen Presentation. Leukemia and lymphoma, 45(2), 363-371.
  • Brown, R., Murray, A., Pope, B., Sze, D., Gibson, J., Ho, J., Hart, D., Joshua, D. (2004). Either Interleukin-12 Or Interferon-γ Can Correct The Dendritic Cell Defect Induced By Transforming Growth Factor β�? In Patients With Myeloma. British Journal of Haematology, 125(2), 743-748.
  • Gibson, J., Ho, J., Joshua, D. (2004). Evolving Transplant Options For Multiple Myeloma: Autologous And Nonmyeloablative Allogenic. Transplantation Proceedings, 36(8), 2501-2503. [More Information]
  • Gibson, J., Ho, J., Joshua, D. (2004). Low-Grade Lymphoma: The Optimal Timing. Transplantation Proceedings, 36(7), 1995-1998. [More Information]
  • Ho, J., Gibson, J., Joshua, D. (2004). Treatment Of Multiple Myeloma: Current Management And New Approaches. American Journal of Cancer, 3(1), 47-66.
  • Sze, D., Brown, R., Yuen, E., Gibson, J., Ho, J., Raitakari, M., Basten, A., Joshua, D., Fazekas, B. (2003). Clonal Cytotoxic T Cells in Myeloma. Leukemia and lymphoma, 44(10), 1667-1674.
  • Sze, D., Brown, R., Yang, S., Gibson, J., Ho, J., Fazekas, B., Basten, A., Joshua, D. (2003). Prediction of high affinity class I-restricted multiple myeloma idiotype peptide epitopes. Leukemia and lymphoma, 44(9), 1557-1568.
  • Ho, J. (2002). Chromosomal and genetic abnormalities in myeloma. Clinical and Laboratory Haematology, , 259-269.
  • Ho, J., Gibson, J., Joshua, D., Campbell, L., Brown, R. (2002). The biology and cytogenetics of multiple myeloma. Reviews in Clinical and Experimental Hematology, 6(3), 276-300.
  • Sze, D., Giesajtis,, G., Brown, R., Raitakari, M., Gibson, J., Ho, J., Baxter, A., Fazekas, B., Basten, A., Joshua, D. (2001). Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8+Cd57+CD28- compartment. Blood, 98(9), 2817-2827.
  • Ho, J., Basten, A., Gibson, J., Joshua, D., Brown, R., Pelka, G. (2001). Illegitimate switch recombinations are present in approximately half of primary myeloma tumors, but do not relate to known prognostic indicators or survival. Blood, 97, 490-495.
  • Ho, J., Thein, S. (2000). Gene regulation and deregulation: a beta globin perspective. Blood Reviews, 14, 78-93.

2014

  • Favaloro, J., Brown, R., Aklilu, E., Yang, S., Suen, H., Hart, D., Fromm, P., Gibson, J., Khoo, L., Ho, J., Joshua, D. (2014). Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive state. Leukemia and Lymphoma, 55(5), 1090-1098. [More Information]

2013

  • Bryant, C., Suen, H., Brown, R., Yang, S., Favaloro, J., Aklilu, E., Gibson, J., Ho, J., Iland, H., Fromm, P., Hart, D., Joshua, D., et al (2013). Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance. Blood Cancer Journal, 3, 1-7. [More Information]

2012

  • Ling, S., Lau, K., Al-Shabeeb, A., Nikolic, A., Catalano, A., Iland, H., Horvath, N., Ho, J., Harrison, S., Fleming, S., Joshua, D., Allen, J. (2012). Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1. Haematologica: the hematology journal, 97(1), 64-72. [More Information]
  • Ho, J., Brown, R., Spencer, A., Jeffels, M., Daniher, D., Gibson, J., Joshua, D. (2012). Thalidomide consolidation improves progression-free survival in myeloma with normal but not up-regulated expression of fibroblast growth factor receptor 3: analysis from the Australasian Leukaemia and Lymphoma Group MM6 clinical trial. Leukemia and Lymphoma, 53(9), 1728-1734. [More Information]

2011

  • Ho, J., Tay, L., Lindeman, R., Catley, L., Bowden, D. (2011). Australian guidelines for the assessment of iron overload and iron chelation in transfusion-dependent thalassaemia major, sickle cell disease and other congenital anaemias. Internal Medicine Journal, 41(7), 516-524. [More Information]
  • Viprakasit, V., Ibrahim, H., Ha, S., Ho, J., Li, C., Chan, L., Chiu, C., Sutcharitchan, P., Habr, D., Domokos, G., et al (2011). Clinical efficacy and safety evaluation of tailoring iron chelation practice in thalassaemia patients from Asia-Pacific: a subanalysis of the EPIC study of deferasirox. International Journal of Hematology (online), 93(3), 319-328. [More Information]

2007

  • Loh, Y., Mo, S., Brown, R., Yamagishi, T., Yang, S., Joshua, D., Ho, P., Gibson, J., Roufogalis, B., Sze, D. (2007). Characteristics of 'side population' as the putative cancer stem cells in myeloma: Cell growth and differentiation capability. Molecular Cancer Therapeutics, 6(12), 3365s-3366s.
  • Sanders, J., Crawford, B., Gibson, J., Ho, J., Iland, H., Joshua, D. (2007). Is there a case for the early use of bisphosphonates in smouldering myeloma and MGUS? (Bisphosphonates in SMM & MGUS). International Journal of Laboratory Hematology, 29(5), 395-397. [More Information]
  • Ling, S., Campbell, L., Ho, J., Gibson, J., Joshua, D. (2007). Molecular Biology, Pathology, and Cytogenetics. In Mikkael A. Sekeres, Matt E. Kalaycio, Brian J. Bolwell (Eds.), Clinical Malignant Haematology, (pp. 847-857). United States: McGraw Hill.
  • Osborn, R., de Abreu Lourenço, R., Dalton, A., Houltram, J., Dowton, D., Joshua, D., Lindeman, R., Ho, J. (2007). Quality of life related to oral versus subcutaneous iron chelation: a time trade-off study. Value in Health, 10(6), 451-456. [More Information]

2006

  • Trent, R., Webster, B., Bowden, D., Gilbert, A., Ho, J., Lindeman, R., Lammi, A., Rowell, J., Hinchcliffe, M., Colley, A., et al (2006). Complex phenotypes in the haemoglobinopathies: recommendations on screening and DNA testing. Pathology, 38(6), 507-519.
  • Sze, D., Brown, R., Yang, S., Ho, J., Gibson, J., Joshua, D. (2006). The use of thalidomide in myeloma therapy as an effective anticancer drug. Current Cancer Drug Targets, 6(4), 325-331. [More Information]
  • Ling, S., Joshua, D., Gibson, J., Young, G., Iland, H., Watson, G., Ho, J. (2006). Transformation and Progression of Waldenström's Macroglobulinemia Following Cladribine Therapy in Two Cases: Natural Evolution or Iatrogenic Causation? American Journal Of Hematology, 81(2), 110-114. [More Information]

2005

  • Brown, R., Ho, J. (2005). Identification of Malignant Plasma Cells by mRNA In Situ Hybridization. Methods in molecular medicine, 113, 175-181.
  • Joshua, D., Brown, R., Ho, J. (2005). Multiple myeloma: challenges and opportunities. Methods in molecular medicine, 113(Multiple Myeloma: Methods and Protocols), 1-4.
  • Ho, J. (2005). Multiple Myeloma: Methods and Protocols. Totowa, NJ, USA: Humana Press.
  • Gibson, J., Joshua, D., Ho, J., Campbell, L., Ling, S. (2005). Multiple Myeloma: molecular biology, Pathology and Cytogenics. In Susan Hallam, Ian Cross, Michael Thaut (Eds.), Oxford Handbook of Music Psychology. Oxford, UK: Oxford University Press.

2004

  • Brown, R., Murray, A., Pope, B., Sze, D., Gibson, J., Ho, J., Joshua, D. (2004). B7+ T Cells In Myeloma: An Acquired Marker Of Prior Chronic Antigen Presentation. Leukemia and lymphoma, 45(2), 363-371.
  • Brown, R., Murray, A., Pope, B., Sze, D., Gibson, J., Ho, J., Hart, D., Joshua, D. (2004). Either Interleukin-12 Or Interferon-γ Can Correct The Dendritic Cell Defect Induced By Transforming Growth Factor β�? In Patients With Myeloma. British Journal of Haematology, 125(2), 743-748.
  • Gibson, J., Ho, J., Joshua, D. (2004). Evolving Transplant Options For Multiple Myeloma: Autologous And Nonmyeloablative Allogenic. Transplantation Proceedings, 36(8), 2501-2503. [More Information]
  • Gibson, J., Ho, J., Joshua, D. (2004). Low-Grade Lymphoma: The Optimal Timing. Transplantation Proceedings, 36(7), 1995-1998. [More Information]
  • Joshua, D., Gibson, J., Brown, R., Ho, J. (2004). The Immune System In Myeloma. In Gosta Garton, Brian Durie, Diana Samson (Eds.), Multiple myeloma and related disorders, (pp. 29-46). UK: Hodder Arnold.
  • Ho, J., Gibson, J., Joshua, D. (2004). Treatment Of Multiple Myeloma: Current Management And New Approaches. American Journal of Cancer, 3(1), 47-66.

2003

  • Sze, D., Brown, R., Yuen, E., Gibson, J., Ho, J., Raitakari, M., Basten, A., Joshua, D., Fazekas, B. (2003). Clonal Cytotoxic T Cells in Myeloma. Leukemia and lymphoma, 44(10), 1667-1674.
  • Sze, D., Brown, R., Yang, S., Gibson, J., Ho, J., Fazekas, B., Basten, A., Joshua, D. (2003). Prediction of high affinity class I-restricted multiple myeloma idiotype peptide epitopes. Leukemia and lymphoma, 44(9), 1557-1568.

2002

  • Ho, J. (2002). Chromosomal and genetic abnormalities in myeloma. Clinical and Laboratory Haematology, , 259-269.
  • Ho, J., Gibson, J., Joshua, D., Campbell, L., Brown, R. (2002). The biology and cytogenetics of multiple myeloma. Reviews in Clinical and Experimental Hematology, 6(3), 276-300.

2001

  • Sze, D., Giesajtis,, G., Brown, R., Raitakari, M., Gibson, J., Ho, J., Baxter, A., Fazekas, B., Basten, A., Joshua, D. (2001). Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8+Cd57+CD28- compartment. Blood, 98(9), 2817-2827.
  • Ho, J., Basten, A., Gibson, J., Joshua, D., Brown, R., Pelka, G. (2001). Illegitimate switch recombinations are present in approximately half of primary myeloma tumors, but do not relate to known prognostic indicators or survival. Blood, 97, 490-495.

2000

  • Ho, J., Thein, S. (2000). Gene regulation and deregulation: a beta globin perspective. Blood Reviews, 14, 78-93.

To update your profile click here. For support on your academic profile contact .